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7‐AAD

:   7‐aminoactinomycin D

APC

:   allophycocyanin

BILN

:   HCV nonstructural protein 3/4A protease inhibitor BILN2061

CEACAM1

:   carcinoembryonic antigen--related cell‐adhesion molecule 1

CFSE

:   carboxy fluorescein succinimidyl ester

CHB

:   chronic hepatitis B

CHC

:   chronic hepatitis C

DAA

:   direct‐acting antiviral agents

DMEM

:   Dulbecco's modified Eagle's medium

FCS

:   fetal calf serum

ELISA

:   enzyme‐linked immunosorbent assay

FGR

:   full genomic replicon

HCC

:   hepatocellular carcinoma

HCV

:   hepatitis C virus

HLA

:   human leukocyte antigen

ICAM

:   intercellular adhesion molecule

IFN

:   interferon

JFH

:   Japanese fulminant hepatitis

KO

:   knockout

mAb

:   monoclonal antibody

mRNA

:   messenger RNA

MIC

:   major histocompatibility complex class I chain‐related gene

NK cells

:   natural killer cells

NS5A

:   nonstructural protein 5A

PBMC

:   peripheral blood mononuclear cell

PE

:   phycoerythrin

qRT‐PCR

:   reverse‐transcription real‐time PCR

SGR

:   subgenomic replicon

PVR

:   poliovirus receptor

SVR

:   sustained virological response

ULBP

:   UL16 binding protein

Hepatitis C virus (HCV) infection carries a risk of progression to liver cirrhosis or hepatocellular carcinoma (HCC), which is a poor prognostic factor for patients with chronic hepatitis C (CHC).[1](#hep41240-bib-0001){ref-type="ref"} Recently, direct‐acting antiviral agents (DAAs) have become standard treatments for HCV, and DAA therapy produces a sustained virological response (SVR) in 90% to 95% of patients.[2](#hep41240-bib-0002){ref-type="ref"} Although DAA therapy has improved the SVR rate, investigation of immunoregulatory mechanisms in patients with CHC is required to develop new therapies that can achieve complete eradication of HCV. The role of the immunological surveillance system in the development of HCC requires attention and further investigation to elucidate new strategies for HCC treatment.

Natural killer cells (NK cells) play crucial roles in chronic liver diseases.[3](#hep41240-bib-0003){ref-type="ref"}, [4](#hep41240-bib-0004){ref-type="ref"}, [5](#hep41240-bib-0005){ref-type="ref"} The activation of NK cell function inhibits HCV replication, suggesting that impairment of NK cell function leads to persistent infection with HCV.[6](#hep41240-bib-0006){ref-type="ref"} According to Guerra et al., knockout of the NKG2D gene inhibits NK cell cytotoxicity and increases tumor burden in a spontaneous tumor model.[7](#hep41240-bib-0007){ref-type="ref"} In patients with HCC, both cytotoxicity and interferon‐γ (IFN‐γ) production in intrahepatic and peripheral NK cells are impaired.[8](#hep41240-bib-0008){ref-type="ref"} Impaired NK cell function in patients with CHC is believed to lead to persistent HCV infection and HCC development. Therefore, elucidating the mechanism by which NK cell activity is suppressed in response to HCV infection is essential for improving prognosis in patients with CHC.

NK cells are controlled by a balance of activation and inhibition.[3](#hep41240-bib-0003){ref-type="ref"}, [9](#hep41240-bib-0009){ref-type="ref"} Altered NK receptor expression on NK cells is associated with pathogenesis of CHC[4](#hep41240-bib-0004){ref-type="ref"}, [6](#hep41240-bib-0006){ref-type="ref"}, [10](#hep41240-bib-0010){ref-type="ref"}, [11](#hep41240-bib-0011){ref-type="ref"}, [12](#hep41240-bib-0012){ref-type="ref"} However, ligands for NK receptors have not yet been fully investigated in patients with CHC. Carcinoembryonic antigen--related cell‐adhesion molecule 1 (CEACAM1) inhibits NK cell function.[13](#hep41240-bib-0013){ref-type="ref"} CEACAM1 is regarded as both a receptor and ligand for NK cells. Generally, CEACAM1 is expressed on lymphocytes, myelocytes, dendritic cells, epithelial cells, and endothelial cells. CEACAM1 is associated with inflammation, angiogenesis, and immune response to cancer and infections.[14](#hep41240-bib-0014){ref-type="ref"} CEACAM1 expression in the liver is associated with disease progression of HCC.[15](#hep41240-bib-0015){ref-type="ref"} However, the role of CEACAM1 in CHC is not completely understood.

In this study, we examined the role of CEACAM1 in NK cell function in patients with CHC. CEACAM1 expression was induced by the HCV E2 glycoprotein in HCV infection and subsequently reduced NK cell cytotoxicity, which may be associated with persistent infection and the development of HCC.

Materials and Methods {#hep41240-sec-0002}
=====================

Cells and Viruses {#hep41240-sec-0003}
-----------------

Huh7.5.1 cells, HEK293T cells, and Huh7.5.1 cells infected with JFH‐1 (Huh7.5.1/JFH‐1 cells) were cultured in Dulbecco's modified Eagle's medium (DMEM; Nacalai Tesque, Japan) containing 10% heat‐inactivated fetal calf serum (FCS), 100 U/mL penicillin, and 100 μg/ml streptomycin. Huh7 cells harboring the HCV subgenomic replicon of the JFH‐1 (SGR) or the full genomic replicon of the JFH‐1 (FGR) were cultured in DMEM supplemented with 10% heat‐inactivated FCS and 1 mg/mL G418 (Nacalai Tesque).[16](#hep41240-bib-0016){ref-type="ref"} K562 cells and human NK cells were cultured in RPMI‐1640 medium (DMEM; Sigma, St. Louis, MO) containing 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% heat‐inactivated FCS. Further details are described in the Supporting Information.

Knockout of CEACAM1 in Huh7.5.1 Cells {#hep41240-sec-0004}
-------------------------------------

We generated CEACAM1 knockout (KO) Huh7.5.1 cells using the CRISPR/Cas9 system according to previously described methods.[17](#hep41240-bib-0017){ref-type="ref"} We confirmed CEACAM1 deficiency in monoclonal cells by flow cytometry and enzyme‐linked immunosorbent assay (ELISA).

*Separation of Human Peripheral Blood Mononuclear and NK Cells* {#hep41240-sec-0005}
---------------------------------------------------------------

Peripheral blood mononuclear cells (PBMCs) were separated by Ficoll‐Hypaque density centrifugation. NK cells were isolated from PBMCs using an NK isolation kit (Miltenyi Biotech, CA). We defined NK cells as CD3^‐^CD56^+^ cells and confirmed that purity was greater than 90% by flow cytometry.

Flow Cytometry {#hep41240-sec-0006}
--------------

Huh7.5.1 cells and Huh7.5.1/JFH‐1 cells were incubated for 20 minutes with the following antibodies: BAT3 (EPR9223), intercellular adhesion molecule 1 (ICAM1)‐phycoerythrin (PE) (LB‐2), ICAM2‐PE (CBR‐1C2/2), nectin‐2‐PE (R2.525), major histocompatibility complex class I chain‐related gene (MIC)A/B‐PE (6D4), human leukocyte antigen (HLA)‐A, B, C‐PE (G46‐2.6), poliovirus receptor (PVR)‐PE (SKII.4), HLA‐E‐PE (3D12), HLA‐G‐PE (87G), UL16 binding protein 1 (ULBP1)‐allophycocyanin (APC) (170818), ULBP2/5/6‐PE (165903), ULBP3‐APC (166510), and CEACAM1‐PE (283340). Only BAT3 required a secondary antibody (Alexa Fluor 488 \[Cell Signaling Technology, Danvers, MA\]). We analyzed the expression of these proteins using a FACS Canto II flow cytometer (BD Biosciences, Franklin Lakes, NJ) and DIVA software (BD Biosciences).

ELISA {#hep41240-sec-0007}
-----

Serum CEACAM1 levels and CEACAM1 in supernatants were examined using a CEACAM1 ELISA kit (R&D Systems, CA).

*Reverse‐Transcription Real‐Time PCR and RNA Silencing* {#hep41240-sec-0008}
-------------------------------------------------------

See [Supporting Information](#hep41240-sup-0006){ref-type="supplementary-material"} for details.

*Evaluation of NK Cytotoxicity* {#hep41240-sec-0009}
-------------------------------

Carboxy fluorescein succinimidyl ester (CFSE)‐labeled K562 cells (1.5 × 10^5^/well) were added to naïve NK cells (1.5 × 10^5^/well) at an effector cell to target cell (E/T) ratio of 1:1 and incubated at 37°C for 6 hours. After incubation, 7‐aminoactinomycin D (7‐AAD) was added to the cells, and cytotoxicity was measured by flow cytometry. NK cytotoxicity toward CFSE‐labeled K562 cells was calculated using a previously described method.[18](#hep41240-bib-0018){ref-type="ref"}

CD107a Degranulation Assay and Evaluation of Intracellular IFN‐γ Expression {#hep41240-sec-0010}
---------------------------------------------------------------------------

K562 cells and human NK cells were cocultured at an E/T ratio of 1:1. We added an antihuman CD107a monoclonal antibody (mAb) and incubated the coculture for 1 hour. Subsequently, we added GolgiPlug (1:1000, BD Biosciences) to the coculture and incubated the cells for an additional 3 hours, followed by staining with CD3 and CD56 mAbs. Next, we permeabilized the cells with Cytofix/Cytoperm and Perm/Wash Buffer (BD Bioscience) and stained the cells with an IFN‐γ mAb. CD107a expression on NK cells and intracellular IFN‐γ expression were evaluated by flow cytometry.

Transwell Assay {#hep41240-sec-0011}
---------------

Huh7.5.1/JFH‐1 cells (5.0 × 10^4^/well) were cultured in the bottom of a 96‐well Transwell cell culture system (pore size 3.0 μm; Corning, Japan), and NK cells (1.5 × 10^5^/well) were cultured on the membranes of the Transwell cell culture inserts. After 24 hours of coculture in Transwells, CFSE‐labeled K562 cells (1.5 × 10^5^/well) were added to the membranes of Transwell cell culture inserts in each well, and the plate was incubated for 6 hours. Subsequently, the cytotoxicity toward CFSE‐labeled K562 cells was calculated.

Reagents {#hep41240-sec-0012}
--------

ICAM2‐PE, nectin‐2‐PE, MICA/B‐PE HLA‐A, B, C‐PE CD3‐BV510, CD56‐BV421, and CD107a‐APC antibodies were purchased from BD Biosciences. CEACAM1‐PE, ULBP1‐APC, ULBP2/5/6‐PE, and ULBP3‐APC antibodies were purchased from R&D Systems. The 7‐AAD Viability Staining Solution, PVR‐PE, HLA‐E‐PE, and HLA‐G‐PE were purchased from BioLegend (San Diego, CA). The BAT3 antibody was purchased from Abcam (Cambridge, UK). The ICAM1‐PE antibody was purchased from Becton Dickinson Immunocytometry Systems (San Jose, CA). We purchased the NK Cell Isolation Kit from Miltenyi Biotec (California), the Vybrant CFDA SE Cell Tracer Kit from Life Technologies (Ontario, Canada), and the HCV nonstructural protein 3/4A protease inhibitor BILN2061 (BILN) from Acme Bioscience (Belmont, CA).[19](#hep41240-bib-0019){ref-type="ref"}

Overexpression of the HCV Core Protein and HCV E1 and E2 Glycoproteins in Huh7.5.1 Cells Using a Lentiviral Vector System {#hep41240-sec-0013}
-------------------------------------------------------------------------------------------------------------------------

We designed complementary DNAs encoding the HCV core protein, E1 glycoprotein, and E2 glycoprotein. We generated the overexpression models using a previously described method.[20](#hep41240-bib-0020){ref-type="ref"}

Immunofluorescence Staining of Huh7.5.1/JFH‐1 Cells {#hep41240-sec-0014}
---------------------------------------------------

Immunostaining for nonstructural protein 5A (NS5A) in Huh7.5.1/JFH‐1 cells cultured in 48‐well plates was performed as previously described.[19](#hep41240-bib-0019){ref-type="ref"}, [21](#hep41240-bib-0021){ref-type="ref"} Stained cells were analyzed using a fluorescence microscope (BZ‐9000; Keyence, Japan).

Human Subjects {#hep41240-sec-0015}
--------------

This study enrolled 24 healthy subjects, 27 patients with CHC, 46 patients who were treated with PEGylated IFN‐α plus ribavirin and achieved an SVR, 9 patients with chronic hepatitis B (CHB), 19 patients with NASH, 8 patients who achieved an SVR with sofosbuvir/ledipasvir, and 23 patients with HCC. For analysis of NK cell function, 23 patients with CHC were enrolled to analyze NK cell function. Eleven healthy subjects and 46 patients with CHC were enrolled to analyze messenger RNA (mRNA) levels in human liver tissues. All of the healthy subjects were negative for HCV and hepatitis B virus and had no history of immunological diseases, liver diseases, or malignant diseases. This human study was approved by the Ethics Committee of Osaka University Graduate School of Medicine. Written informed consent was received from all of the participants.

Statistical Analysis {#hep41240-sec-0016}
--------------------

For comparison of two groups, Wilcoxon signed‐rank tests, Mann‐Whitney tests, paired t‐test, and linear regression analyses were performed with the JMP 13.0 software package (SAS Institute, North Carolina). For multiple comparison, one‐way analysis of variance was performed followed by the Tukey honestly significant difference test with the JMP 13.0 software package. *P* values less than 0.05 were considered significant.

Results {#hep41240-sec-0017}
=======

CEACAM1 Expression in JFH‐1 Infected Huh7.5.1 Cells {#hep41240-sec-0018}
---------------------------------------------------

First, we examined the expression levels of molecules regulating NK cell function on Huh7.5.1 cells and JFH‐1‐infected Huh7.5.1 cells (Huh7.5.1/JFH‐1 cells). The analyzed ligands that activate or inhibit receptors on NK cells were as follows: BAT3, ICAM‐1, ICAM‐2, nectin‐2, PVR, MICA/B, ULBP1, ULBP2/5/6, ULBP3, HLA‐A, B, C, ‐E, HLA‐G, and CEACAM1. Among these ligands, CEACAM1 expression was clearly increased in cells infected with JFH‐1 (Fig. [1](#hep41240-fig-0001){ref-type="fig"}A,B), which encouraged us to focus on CEACAM1 expression. We measured the concentration of CEACAM1 in the supernatant and the level of CEACAM1 mRNA in Huh7.5.1/JFH‐1 cells. Significantly higher levels of CEACAM1 were detected in the supernatant of Huh7.5.1/JFH‐1 cells than in the supernatant of Huh7.5.1 cells, and significantly higher levels of CEACAM1 mRNA were observed in Huh7.5.1/JFH‐1 cells than in Huh7.5.1 cells (Fig. [1](#hep41240-fig-0001){ref-type="fig"}B). Both CEACAM1 expression on the cells and CEACAM1 levels in the supernatant depended on the time of JFH‐1 infection, and CEACAM1 levels in the supernatant correlated with the surface CEACAM1 level (Fig. [1](#hep41240-fig-0001){ref-type="fig"}C,D). We treated Huh7.5.1/JFH‐1 cells with BILN to determine the influence of HCV on CEACAM1 expression. NS5A expression was decreased in Huh7.5.1/JFH‐1 cells treated with BILN compared with untreated cells (Fig. [1](#hep41240-fig-0001){ref-type="fig"}E). Significantly lower levels of CEACAM1 were expressed on Huh7.5.1/JFH‐1 cells treated with BILN than on untreated Huh7.5.1/JFH‐1 cells. Consistent with this finding, significantly lower levels of CEACAM1 mRNA were observed in Huh7.5.1/JFH‐1 cells treated with BILN than in untreated Huh7.5.1/JFH‐1 cells (Fig. [1](#hep41240-fig-0001){ref-type="fig"}F). These data suggest that HCV regulates CEACAM1 expression.

![CEACAM1 expression increased on Huh7.5.1 cells infected with JFH‐1 and decreased after treatment. (A) Expression of ligands for NK cells, such as BAT3, ICAM‐1, ICAM‐2, nectin‐2, PVR, MICA/B, ULBP1, ULBP2/5/6, ULBP3, HLA‐A, B, C, HLA‐E, HLA‐G and CEACAM1, was analyzed on Huh7.5.1 cells and Huh7.5.1 cells infected with JFH‐1 (Huh7.5.1/JFH‐1 cells). The dotted line represents Huh7.5.1 cells, the solid line represents Huh7.5.1/JFH‐1 cells, and the shaded area represents the isotype control. (B) CEACAM1 expression on Huh7.5.1 cells and Huh7.5.1/JFH‐1 cells was analyzed by flow cytometry (left panel, means ± SD, n = 4). CEACAM1 levels in the supernatants of Huh7.5.1 cells and Huh7.5.1/JFH‐1 cells were analyzed by ELISA (middle panel, means ± SD, n = 4). In addition, levels of the CEACAM1 mRNA in Huh7.5.1 cells and Huh7.5.1/JFH‐1 cells were analyzed by qRT‐PCR (right panel, means ± SD, n = 4). (C,D) CEACAM1 levels at the cell surface and in supernatants of Huh7.5.1/JFH‐1 cells were measured by flow cytometry and ELISA, respectively, at the indicated times after infection (means ± SD, n = 4). (E) Immunofluorescence staining for NS5A (green) and 4',6‐diamidino‐2‐phenylindole (DAPI; blue) was performed in Huh7.5.1/JFH‐1 (left panel) cells and Huh7.5.1/JFH‐1 cells treated with BILN (right panel). Levels of JFH‐1 mRNA in Huh7.5.1/JFH‐1 cells before and after treatment were evaluated by qRT‐PCR (means ± SD, n = 4). (F) Analysis of Huh7.5.1 cells, Huh7.5.1 cells + BILN, Huh7.5.1/JFH‐1 cells, and Huh7.5.1/JFH‐1 cells + BILN. CEACAM1 expression on these cells was analyzed by flow cytometry (means ± SD, n = 4). Levels of CEACAM1 mRNA in these cells were evaluated by qRT‐PCR (means ± SD, n = 4). ^\*^ *P* \< 0.05.](HEP4-2-1247-g001){#hep41240-fig-0001}

Naïve NK Cells Displayed Increased Cytotoxicity Toward K562 Cells After Coculture With CEACAM1 Knockout Huh7.5.1/JFH‐1 Cells Compared With Huh7.5.1/JFH‐1 Cells {#hep41240-sec-0019}
---------------------------------------------------------------------------------------------------------------------------------------------------------------

We generated CEACAM1 KO Huh7.5.1 cells and CEACAM1 KO Huh7.5.1/JFH‐1 cells using the CRISPR/Cas9 system to determine whether CEACAM1 expression on Huh7.5.1 cells controls NK cell activity. According to the results of the flow cytometry analysis, neither CEACAM1 KO Huh7.5.1 cells nor CEACAM1 KO Huh7.5.1/JFH‐1 cells expressed CEACAM1 on their surfaces (Fig. [2](#hep41240-fig-0002){ref-type="fig"}A). The CEACAM1 protein was not detected in the supernatants from CEACAM1 KO Huh7.5.1 cells or CEACAM1 KO Huh7.5.1/JFH‐1 cells (Fig. [2](#hep41240-fig-0002){ref-type="fig"}B). Immunohistochemistry staining for NS5A revealed an equivalent efficiency of JFH‐1 infection between Huh7.5.1/JFH‐1 cells and CEACAM1 KO Huh7.5.1/JFH‐1 cells (Fig. [2](#hep41240-fig-0002){ref-type="fig"}C). With the exception of CEACAM1, the expression of ligands for receptors that activate and inhibit NK cells did not differ between CEACAM1 KO Huh7.5.1 cells and Huh7.5.1 cells. Similar results were observed in CEACAM1 KO Huh7.5.1/JFH‐1 cells and Huh7.5.1/JFH‐1 cells (Supporting Fig. [S1](#hep41240-sup-0001){ref-type="supplementary-material"}).

![Naïve NK cell cytotoxicity toward K562 cells was increased by coculture with CEACAM1 KO Huh7.5.1/JFH‐1 cells compared with Huh7.5.1/JFH‐1 cells. (A,B) CEACAM1 KO Huh7.5.1 cells were generated using the CRISPR/Cas9 system. Flow cytometry and ELISA were used to confirm that the CEACAM1 KO Huh7.5.1 cells and CEACAM1 KO Huh7.5.1/JFH‐1 cells did not express CEACAM1 at the cell surface and in supernatants, respectively. (C) Immunofluorescence staining for NS5A (green) and DAPI (blue) was performed in Huh7.5.1/JFH‐1 cells (left panel) and CEACAM1 KO Huh7.5.1/JFH‐1 cells (right panel). The efficiency of infection in Huh7.5.1/JFH‐1 cells was similar to CEACAM1 KO Huh7.5.1/JFH‐1 cells, as determined by qRT‐PCR (means ± SD, n = 4). (D) CFSE‐labeled K562 cells were added after 24 hours of NK cell coculture with Huh7.5.1 cells, Huh7.5.1/JFH‐1 cells, or CEACAM1 KO Huh7.5.1/JFH‐1 cells, and cocultures were incubated at 37°C. After 6 hours of incubation, 7‐AAD was added, and cytotoxicity was measured by flow cytometry (means ± SD, n = 4). NK cells were incubated with K562 cells and subjected to flow cytometry, to evaluate the expression of CD107a (means ± SD, n = 4) and the intracellular expression of IFN‐γ (means ± SD, n = 4). Representative data obtained from the peripheral NK cells of healthy subjects are shown. ^\*^ *P* \< 0.05. **^§^**Not detected. Abbreviation: N.S., not significant.](HEP4-2-1247-g002){#hep41240-fig-0002}

Naïve NK cells were isolated from healthy subjects and cocultured with Huh7.5.1 cells, Huh7.5.1/JFH‐1 cells, or CEACAM1 KO Huh7.5.1/JFH‐1 cells. NK cells displayed significantly greater cytotoxicity toward K562 cells, an NK‐sensitive cell line, after coculture with CEACAM1 KO Huh7.5.1/JFH‐1 cells than coculture with Huh7.5.1/JFH‐1 cells (Fig. [2](#hep41240-fig-0002){ref-type="fig"}D). Significantly higher levels of the cytotoxic marker CD107a and IFN‐γ were expressed in NK cells cocultured with CEACAM1 KO Huh7.5.1/JFH‐1 cells than in NK cells cocultured with Huh7.5.1/JFH‐1 cells (Fig. [2](#hep41240-fig-0002){ref-type="fig"}D). Thus, CEACAM1 expressed on HCV‐infected Huh7.5.1 cells controls the cytotoxicity and IFN‐γ production of NK cells.

Cell--Cell Contact Was Required to Suppress NK Cell Function {#hep41240-sec-0020}
------------------------------------------------------------

We applied the Transwell culture system to analyze the mechanism by which NK cell function is suppressed. In the Transwell experiments, NK cell cytotoxicity was similar following coculture with Huh7.5.1/JFH‐1 compared with coculture with CEACAM1 KO Huh7.5.1/JFH‐1 cells. In the absence of the Transwell, NK cells cocultured with Huh7.5.1/JFH‐1 cells displayed significantly less cytotoxicity than NK cells cocultured with CEACAM1 KO Huh7.5.1/JFH‐1 cells (Fig. [3](#hep41240-fig-0003){ref-type="fig"}A). CD107a expression on NK cells and intracellular IFN‐γ production in NK cells showed similar results to the cytotoxicity assay (Fig. [3](#hep41240-fig-0003){ref-type="fig"}B,C). Based on these results, cell--cell contact is required to suppress NK cell function.

![CEACAM1‐mediated suppression of NK cell function required cell--cell contact. (A‐C) Huh7.5.1/JFH‐1 cells were cultured in the bottom of the 96‐well Transwell cell culture system, and NK cells were cultured on the membrane of the Transwell cell culture inserts or in the bottom of the plate. After 24 hours of coculture in a Transwell, CFSE‐labeled K562 cells were added to NK cells and incubated for 6 hours. We subsequently measured the degree of cytotoxicity toward K562 cells (A), CD107a expression on NK cells (B), and IFN‐γ expression in NK cells (C) using flow cytometry (means ± SD, n = 4). Representative data obtained from the peripheral NK cells of healthy subjects are shown. ^\*^ *P* \< 0.05.](HEP4-2-1247-g003){#hep41240-fig-0003}

HCV E2 Glycoprotein Increased CEACAM1 Expression on Huh7.5.1/JFH‐1 Cells {#hep41240-sec-0021}
------------------------------------------------------------------------

CEACAM1 expression on SGR cells was equivalent to that of SGR cells treated with DAAs (Fig. [4](#hep41240-fig-0004){ref-type="fig"}A), but significantly higher levels of CEACAM1 were expressed on FGR cells than on FGR cells treated with DAAs (Fig. [4](#hep41240-fig-0004){ref-type="fig"}B). FGR cells expressed the HCV core protein, E1 glycoprotein and E2 glycoprotein, but SGR cells did not. We transiently overexpressed the HCV core protein, E1 glycoprotein, and E2 glycoprotein in Huh7.5.1 cells using lentiviral vectors, and CEACAM1 expression on these cells was measured by flow cytometry. Higher levels of the CEACAM1 protein were detected in cells overexpressing the HCV E2 glycoprotein but not with overexpression of the HCV core protein or HCV E1 glycoprotein (Fig. [4](#hep41240-fig-0004){ref-type="fig"}C). Therefore, the HCV E2 glycoprotein may increase CEACAM1 expression.

![The HCV E2 glycoprotein may upregulate CEACAM1 expression on Huh7.5.1/JFH‐1 cells. (A) CEACAM1 expression on untreated and treated SGR cells was analyzed by flow cytometry (means ± SD, n = 4). (B) CEACAM1 expression on untreated and treated FGR cells was measured by flow cytometry (means ± SD, n = 4). (C) We overexpressed the HCV core protein, E1 glycoprotein, and E2 glycoprotein in Huh7.5.1 cells using a lentiviral vector system. CEACAM1 expression on these cells was evaluated by flow cytometry (means ± SD, n = 4). The shaded area represents the isotype control, the solid line represents mock‐infected cells, and the dotted line represents overexpressing cells. ^\*^ *P* \< 0.05.](HEP4-2-1247-g004){#hep41240-fig-0004}

Serum CEACAM1 Levels and NK Cell Functions in Patients With CHC {#hep41240-sec-0022}
---------------------------------------------------------------

We analyzed serum CEACAM1 levels in 24 healthy subjects, 27 patients with CHC, 46 patients who achieved an SVR treated with IFN, 9 patients with CHB, and 19 patients with NASH using an ELISA (Table [1](#hep41240-tbl-0001){ref-type="table"}). Significantly higher serum CEACAM1 levels were detected in patients with CHC than in healthy subjects, patients with CHB, and patients with NASH. Significantly lower serum CEACAM1 levels were detected in patients who achieved an SVR than in patients with CHC (Fig. [5](#hep41240-fig-0005){ref-type="fig"}A). In the 27 patients with CHC, serum CEACAM1 levels correlated significantly with serum HCV viral loads (Fig. [5](#hep41240-fig-0005){ref-type="fig"}B). We also examined serum CEACAM1 levels of patients who achieved an SVR with sofosbuvir/ledipasvir using sequential stored serum samples. Serum CEACAM1 levels at 24 weeks after the end of treatment were same as those at the end of treatment, and both were significantly lower than those at pretreatment (Supporting Fig. [S2](#hep41240-sup-0002){ref-type="supplementary-material"}). Thus, elevated serum CEACAM1 levels may be associated with HCV infection.

###### 

Clinical Characteristics of Patient‐Examined Serum CEACAM1 Levels

                                       HS           CHC                                                   SVR            CHB           NASH
  ------------------------------------ ------------ ----------------------------------------------------- -------------- ------------- -----------------------------------------------------
  Number of patients                   23           27                                                    46             9             19
  Sex, male/female                     13/10        13/14                                                 26/20          5/4           5/14
  Age, years, median (range)           69 (41‐78)   65 (29‐81)                                            63.5 (25‐74)   51 (31‐78)    65 (30‐80)
  AST, IU/L, median (range)            21 (12‐33)   67 (20‐365)[\*](#hep41240-note-0005){ref-type="fn"}   22 (12‐188)    33 (20‐108)   54 (23‐137)[\*](#hep41240-note-0005){ref-type="fn"}
  ALT, IU/L, median (range)            16 (9‐41)    58 (10‐313)[\*](#hep41240-note-0005){ref-type="fn"}   20 (6‐214)     32 (14‐199)   72 (18‐181)[\*](#hep41240-note-0005){ref-type="fn"}
  HCV‐RNA, log IU/mL, median (range)   Not tested   6.4 (4.6‐7.4)                                         Undetected     Not tested    Not tested

^\*^ *P* \< 0.05 versus HS and SVR.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HS, healthy subject.

John Wiley & Sons, Ltd

![Serum CEACAM1 levels and CD107a expression on NK cells in patients with CHC. (A) Serum CEACAM1 levels were measured in healthy subjects, patients with CHC, patients who achieved an SVR, patients with CHB, and patients with NASH using an ELISA. (B) In patients with CHC, serum CEACAM1 levels correlated significantly with serum HCV‐RNA loads. (C) We examined serum CEACAM1 levels using an ELISA and CD107a expression on NK cells cocultured with K562 cells by flow cytometry. In 23 patients with CHC, serum CEACAM1 levels were inversely correlated with CD 107a expression on NK cells. (D) We measured CD107a expression on naïve NK cells in 15 of 23 patients with CHC before and after treatment by flow cytometry. (E) Serum CEACAM1 levels in all 15 patients shown in (D) were analyzed before and after treatment using an ELISA. (F) Using qRT‐PCR, we examined levels of CEACAM1 mRNA in 11 liver tissues obtained from uninfected patients through a hepatectomy and from 46 liver tissues obtained from patients with CHC through a liver biopsy.](HEP4-2-1247-g005){#hep41240-fig-0005}

We next analyzed NK cell functions in 23 patients with CHC (Table [2](#hep41240-tbl-0002){ref-type="table"}). NK cell functions were evaluated by determining the expression of CD107a, a marker of NK cytotoxicity, on NK cells. Serum CEACAM1 levels were negatively correlated with CD107a expression on NK cells in patients with CHC (R = 0.488, *P* \< 0.05) (Fig. [5](#hep41240-fig-0005){ref-type="fig"}C). Based on these data, elevated CEACAM1 levels are associated with decreased NK cell function in patients with CHC. Matched NK cells and serum samples were collected from 15 of the 23 patients with CHC before and after treatment. The expression of CD107a on NK cells in these 15 samples was analyzed at 48 weeks after treatment (Table [2](#hep41240-tbl-0002){ref-type="table"}). CD107a expression on NK cells increased in 14 of 15 patients after treatment compared with the pretreatment level (Fig. [5](#hep41240-fig-0005){ref-type="fig"}D). Serum CEACAM1 concentrations of all 15 patients decreased after treatment (Fig. [5](#hep41240-fig-0005){ref-type="fig"}E).

###### 

Clinical Characteristics of Patient‐Examined NK Cell function

                                       Pretreatment    Posttreatment
  ------------------------------------ --------------- ---------------
  Number of patients                   23              15
  Sex, male/female                     7/16            3/12
  Age, years, median (range)           68 (48‐90)      69 (49‐75)
  AST, IU/L, median (range)            34 (20‐116)     20 (18‐31)
  ALT, IU/L, median (range)            32 (14‐106)     14 (7‐25)
  HCV‐RNA, log IU/mL, median (range)   6.3 (3.8‐7.1)   Undetected

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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Higher Levels of the CEACAM1 mRNA Were Detected in Liver Tissues From Patients With CHC Than in Tissues From Healthy Subjects {#hep41240-sec-0023}
-----------------------------------------------------------------------------------------------------------------------------

We also examined liver expression of CEACAM1 in patients with CHC. Levels of CEACAM1 mRNA were analyzed in 11 healthy subjects and 46 patients with CHC using reverse‐transcription real‐time PCR (qRT‐PCR) (Table [3](#hep41240-tbl-0003){ref-type="table"}). In healthy subjects, we extracted total RNA from liver tissues (no tumor) obtained during a hepatectomy, and we extracted total RNA from liver biopsy samples obtained from patients with CHC. Significantly higher levels of the CEACAM1 mRNA were found in patients with CHC than in healthy subjects (Fig. [5](#hep41240-fig-0005){ref-type="fig"}F).

###### 

Clinical Characteristics of Patient‐Examined CEACAM1 mRNA Levels in Liver Tissues

                                       HS           CHC             *P* Value
  ------------------------------------ ------------ --------------- -----------
  Number of patients                   11           46              ---
  Sex, male/female                     8/3          18/28           NS
  Age, years, median (range)           60 (38‐80)   65 (29‐81)      NS
  AST, IU/L, median (range)            17 (13‐25)   48.5 (20‐365)   \< 0.05
  ALT, IU/L, median (range)            15 (11‐22)   48 (10‐313)     \< 0.05
  HCV‐RNA, log IU/mL, median (range)   Not tested   6.5 (4.1‐7.4)   ---

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase HS, healthy subject; NS, not significant.
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Discussion {#hep41240-sec-0024}
==========

Few studies have identified ligands inhibiting NK cell function in patients with CHC. [22](#hep41240-bib-0022){ref-type="ref"}, [23](#hep41240-bib-0023){ref-type="ref"}, [24](#hep41240-bib-0024){ref-type="ref"} HLA‐E, a ligand that suppresses NK cell function, weakens NK cell activity in patients with CHC.[11](#hep41240-bib-0011){ref-type="ref"}, [25](#hep41240-bib-0025){ref-type="ref"} In this study, CEACAM1 was expressed at higher levels on Huh7.5.1 cells infected with HCV in vitro. Thus, we focused on the role of CEACAM1 in controlling NK cell function and found that HCV‐induced CEACAM1 expression was associated with the suppression of NK cell function. CEACAM1 weakens the activity of NK cells in melanoma cells.[13](#hep41240-bib-0013){ref-type="ref"} In this study, cells infected with HCV‐JFH‐1 exhibited increased levels of the CEACAM1 mRNA, CEACAM1 protein on the cell surface, and soluble CEACAM1 in the supernatant. The increased level of CEACAM1 mRNA in infected cells was reversed in cells treated with the NS3/4A protease inhibitor. Thus, HCV infection controls the increase in CEACAM1 expression. We do not exclude the possibility that other inhibitory ligands have roles in suppressing NK cell activity in patients with CHC. However, in our study, both in vitro and clinical data revealed that CEACAM1 is important in suppressing NK cell activity in patients with CHC.

We focused on the function of CEACAM1 in HCV infection. We constructed CEACAM1 KO Huh7.5.1 cells. CEACAM1 was not expressed on the surface of CEACAM1 KO Huh7.5.1 cells, and CEACAM1 was not detected in the supernatant of the cells. Changes in levels of other ligands on the cells were not detected, and the same infection efficacy was observed between the original cells and the CEACAM1 KO Huh7.5.1 cells. NK cells cocultured with CEACAM1 KO Huh7.5.1/JFH‐1 cells exhibited increased cytotoxicity toward K562 cells, higher expression of CD107a on the NK cells, and greater production of IFN‐γ in NK cells than Huh7.5.1/JFH‐1 cells. Similar results were observed in the experiment in which CEACAM1 was knocked down in uninfected Huh7.5.1 cells (Supporting Fig. [S3](#hep41240-sup-0003){ref-type="supplementary-material"}). We examined the expression of NK receptors, such as CEACAM1, NKG2D and NKG2A, on NK cells cocultured with CEACAM1 KO Huh7.5.1/JFH‐1 cells. The expression of these molecules did not change (Supporting Fig. [S4](#hep41240-sup-0004){ref-type="supplementary-material"}). According to Markel et al., CEACAM1 is an inhibitory ligand that binds to another CEACAM1 molecule on NK cells.[13](#hep41240-bib-0013){ref-type="ref"} Because a blocking antibody for CEACAM1 is not commercially available, we cannot conclude that CEACAM1 expressed on NK cells inhibited NK cell function based on our results. However, we speculate that CEACAM1 expressed on HCV‐infected cells might interact with CEACAM1 expressed on NK cells. We examined whether soluble CEACAM1 or cell--cell contact had a greater influence on NK cells cocultured with CEACAM1 KO Huh7.5.1/JFH‐1 cells. Based on the results of the Transwell assay, cell--cell contacts were required to inhibit NK cell function. Thus, membrane‐bound CEACAM1 on target cells contributes more to the inhibition of NK cell function than does soluble CEACAM1.

We examined the mechanism by which HCV infection induced CEACAM1 expression. CEACAM1 expression on FGR cells decreased following treatment with DAAs. In contrast, CEACAM1 expression on SGR cells did not change following treatment with DAAs. FGR cells expressed the HCV core protein and E1 and E2 glycoproteins, but SGR cells did not. We overexpressed each HCV protein in Huh7.5.1 cells. Only cells overexpressing the HCV E2 glycoprotein exhibited increased CEACAM1 expression. Thus, the HCV E2 glycoprotein might also be involved in inducing CEACAM1 expression on HCV‐infected cells. As shown in the study by Taylor et al., the HCV E2 glycoprotein inhibits the IFN‐inducible protein kinase PKR,[26](#hep41240-bib-0026){ref-type="ref"}, [27](#hep41240-bib-0027){ref-type="ref"} and Crotta et al. reported the inhibition of NK cell activity by the binding of HCV E2 glycoprotein to CD81 on NK cells.[27](#hep41240-bib-0027){ref-type="ref"} In addition to these mechanisms, CEACAM1 expression induced by the HCV E2 glycoprotein might be related to the inhibition of NK cell function. CEACAM1 is upregulated by IFN‐γ, TNF‐α),[28](#hep41240-bib-0028){ref-type="ref"} and IFN‐α.[29](#hep41240-bib-0029){ref-type="ref"} However, E2 overexpression increased CEACAM1 (Fig. [4](#hep41240-fig-0004){ref-type="fig"}C), but not IFN‐α or TNF‐α (data not shown), in Huh7.5.1 cells. IFN‐γ mRNA was not detected in E2 glycoprotein‐overexpressing Huh7.5.1 cells. These data suggest that IFN‐γ, IFN‐α, or TNF‐α are not involved in the underlining mechanisms by which E2 glycoproteins induce CEACAM1. Further study will be needed to clarify the mechanisms of E2‐induced CECAM1 expression.

Based on the clinical data, significantly higher CEACAM1 levels were detected in the sera of patients with CHC than in healthy subjects, patients who achieved an SVR, patients with CHB, and patients with NASH. In patients with CHC, serum CEACAM1 levels correlated with the HCV RNA load. In addition, significantly higher levels of CEACAM1 mRNA were detected in liver tissues from HCV‐infected patients than in liver tissues from uninfected patients. We also investigated the association between serum CEACAM1 levels and NK cell function. Serum CEACAM1 levels were inversely correlated with CD107a expression on NK cells from patients with CHC. Based on these results, the elevated CEACAM1 levels observed in patients with CHC might be associated with impaired cytotoxicity of NK cells. A previous report used immunohistochemical analysis to reveal that liver CEACAM1 expression correlated with the progression of HCC.[15](#hep41240-bib-0015){ref-type="ref"} We examined serum CEACAM1 levels in patients with HCC (Supporting Tables [S1](#hep41240-sup-0005){ref-type="supplementary-material"} and [S2](#hep41240-sup-0005){ref-type="supplementary-material"}). The median serum level (100.8 ng/mL) in HCC patients was significantly higher than that in CHC patients (Fig. [5](#hep41240-fig-0005){ref-type="fig"}A). Therefore, CEACAM1 may be involved in the development of HCC in patients with CHC.

In this study, we focused on CEACAM1 expression in CHC and revealed that CEACAM1 expression during HCV infection decreased NK cell cytotoxicity, which may be related to the development of HCC. Inhibition of CEACAM1 expression could become a new strategy for HCC treatment.
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